Genetic Technologies' Clinical Implementation Study in U.S. Breast Screen Centres

Genetic Technologies Limited (ASX: $GTG) is commencing a clinical implementation study with breast imaging centres across New York, Miami, and Houston in the U.S. The study aims to pilot the integration of the geneType into breast imaging centres, facilitating streamlined care and personalized medicine in the context of breast cancer risk assessment.

Executive Commentary on Clinical Implementation Study

Breast cancer risk assessment is crucial for ensuring quality care at breast centres of excellence. GeneType is revolutionizing risk assessment beyond the current gold standard of care. Its integration into breast imaging centres marks a significant shift in how breast cancer risk is evaluated. By utilizing risk assessment, institutions can tailor surveillance strategies, guide women into appropriate high-risk programs, increase patient awareness of their risk, promote shared decision-making, refine clinical actions regarding breast density notification, improve patient adherence, and pave the way for broader impact across populations. Ultimately, this study heralds a new era of precision medicine in the fight against breast cancer, providing screening and risk-reduction opportunities by identifying more at-risk individuals.

Summary of Genetic Technologies' Clinical Implementation Study

Genetic Technologies Limited (ASX: $GTG) is embarking on a clinical implementation study to integrate geneType into breast imaging centres across the U.S. The study aims to streamline care, empower patients to make better decisions about their screening options, and ensure seamless transitions within the centre's workflow. By incorporating risk-stratified decision-making, enhanced breast density notification and interpretation, increased imaging compliance, and scalability and expansion, the company seeks to revolutionize risk assessment and personalized medicine in the fight against breast cancer. This initiative not only extends the reach of personalized breast cancer risk assessment but also supports the issue of breast density notification while ensuring that at-risk patients receive the necessary attention. The study heralds a new era of precision medicine, providing screening and risk-reduction opportunities by identifying more at-risk individuals.